

SHORT REPORT

# A compound heterozygous mutation in *GPD1* causes hepatomegaly, steatohepatitis, and hypertriglyceridemia

Mugdha Joshi<sup>1,3</sup>, Jacqueline Eagan<sup>1,2,3</sup>, Nirav K Desai<sup>4</sup>, Stephanie A Newton<sup>1,3</sup>, Meghan C Towne<sup>1,3</sup>, Nicholas S Marinakis<sup>1,3</sup>, Kristyn M Esteves<sup>1,2,3</sup>, Sarah De Ferranti<sup>5</sup>, Michael J Bennett<sup>6</sup>, Adam McIntyre<sup>7</sup>, Alan H Beggs<sup>1,3</sup>, Gerard T Berry<sup>\*,1,3</sup> and Pankaj B Agrawal<sup>\*,1,2,3</sup>

The constellation of clinico-pathological and laboratory findings including massive hepatomegaly, steatosis, and marked hypertriglyceridemia in infancy is extremely rare. We describe a child who is presented with the above findings, and despite extensive diagnostic testing no cause could be identified. Whole exome sequencing was performed on the patient and parents' DNA. Mutations in *GPD1* encoding glycerol-3-phosphate dehydrogenase that catalyzes the reversible redox reaction of dihydroxyacetone phosphate and NADH to glycerol-3-phosphate (G3P) and NAD<sup>+</sup> were identified. The proband inherited a *GPD1* deletion from the father determined using copy number analysis and a missense change p.(R229Q) from the mother. *GPD1* protein was absent in the patient's liver biopsy on western blot. Low normal activity of carnitine palmitoyl transferases, CPT1 and CPT2, was present in the patient's skin fibroblasts, without mutations in genes encoding for these proteins. This is the first report of compound heterozygous mutations in *GPD1* associated with a lack of *GPD1* protein and reduction in CPT1 and CPT2 activity.

*European Journal of Human Genetics* (2014) 22, 1229–1232; doi:10.1038/ejhg.2014.8; published online 19 February 2014

**Keywords:** *GPD1*; hypertriglyceridemia; steatohepatitis; hepatomegaly

## INTRODUCTION

*GPD1* (MIM 138420) encodes cytoplasmic NAD-dependent glycerol-3-phosphate dehydrogenase 1 (GPD1), a 349-amino-acid protein of 37.5 kD size that catalyzes the reversible redox reaction of dihydroxyacetone phosphate (DHAP) and NADH to glycerol-3-phosphate (G3P) and NAD<sup>+</sup>.<sup>1,2</sup> *GPD1* together with a mitochondrial enzyme, GPD2 also has an important role in the transport of reducing equivalents from the cytosol to the mitochondria.<sup>2</sup> Recently, a homozygous splicing mutation in *GPD1*, c.361-1G>C, predicted to encode p.Ile119fsX94, was identified in 10 family members from four highly consanguineous Israeli Arab families presenting with early onset hepatomegaly, hepatic steatosis, and hypertriglyceridemia.<sup>2</sup>

Monogenic hypertriglyceridemia is caused by mutations in lipoprotein lipase (*LPL*), apolipoprotein C-II (*APOC2*), glycosylphosphatidylinositol-anchored HDL-binding protein (*GPIHBP1*), ApoA-V (*APOA5*), and lipase maturation factor 1 (*LMF1*).<sup>2–4</sup> Hepatic steatosis as a monogenic disease in early infancy is extremely rare and has been described with Chanarin–Dorfman syndrome due to abhydrolase domain containing 5 (*ABHD5*) mutations, and mitochondrial fatty acid oxidation defects including CPT1A, CPT2, and very long chain acyl-CoA dehydrogenase (*ACADVL*) deficiency.<sup>5–7</sup> These patients often have other features including hypoglycemia, encephalopathy and cardiomyopathy, myopathy, and liver failure.

A combination of profound hypertriglyceridemia and severe hepatomegaly in early infancy is extremely rare.

Here we describe a female patient of Caucasian descent with massive hepatomegaly, fatty liver and severe hypertriglyceridemia carrying a compound heterozygous mutation in *GPD1* (MIM 138420). This is the first instance of a *GPD1* mutation identified outside of the Israeli Arab population. In addition, we show that the *GPD1* protein was absent in the patient's liver tissue. There was no compensatory increase in the GPD2 levels in response to *GPD1* deficiency. Further, although the activity of carnitine palmitoyltransferases CPT1A and CPT2 was reduced in the patient's fibroblasts, no mutations of these genes were identified, and the amount of CPT1A in her liver tissue sample was not altered.

## PATIENT AND METHODS

### Enrollment of patient and sample collection

The patient is a female infant, delivered normally at birth at term gestation and adopted aged three days. Abdominal enlargement was present since birth and a history of frequent spitting up/vomiting prompted an ultrasound at six weeks that ruled out pyloric stenosis. At five months, she was noted to have marked hepatomegaly (liver enlarged 2 cm below the umbilicus) and a small head circumference of 40.5 cm, (5th centile) prompting further evaluation. Liver function tests were abnormal with AST of 4.88  $\mu$ kat/l (normal 0.034–0.68  $\mu$ kat/l),

<sup>1</sup>Division of Genetics and Genomics, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; <sup>2</sup>Division of Newborn Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; <sup>3</sup>The Manton Center for Orphan Disease Research, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; <sup>4</sup>Division of Gastroenterology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; <sup>5</sup>Department of Cardiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; <sup>6</sup>Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; <sup>7</sup>Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada  
\*Correspondence: Dr PB Agrawal or Dr GT Berry, Division of Genetics and Genomics, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA. Tel: +617 919 2153 or +857 218 4636; Fax: +617 730 0253; E-mail: pagrawal@enders.tch.harvard.edu (PBA) or E-mail: gerard.berry@childrens.harvard.edu (GTB)  
Received 19 August 2013; revised 2 January 2014; accepted 8 January 2014; published online 19 February 2014


ALT 2.67  $\mu$ kat/l (normal 0.051–0.92  $\mu$ kat/l), and GGT 6.03  $\mu$ kat/l (normal 0.13–0.58  $\mu$ kat/l). Serum total bilirubin was 6.84  $\mu$ mol/l, within normal limits (reference range: 4–17  $\mu$ mol/l). The liver ultrasound at five months revealed diffuse enlargement and increased echogenicity (Figures 1b and c) and biopsy done few days later showed diffuse and marked micro- and macrovesicular steatosis (Figure 1a), consistent with non-alcoholic steatohepatitis (NASH) or fatty liver disease. No evidence of cholestasis, cytoplasmic inclusions, significant iron deposition, significant inflammation or fibrosis was apparent. A lipid profile revealed significantly elevated plasma triglycerides (9.48 mmol/l; normal 0.57–1.47) and elevated cholesterol (5.1 mmol/l; normal <4.4 mmol/l). Plasma triglycerides remained high; the last level measured at 1.5 years of age was 6.06 mmol/l. An 8-h fasting study revealed no hypoglycemia or urine ketones. Plasma electrophoresis revealed chylomicronemia consistent with Fredrickson's type 5 hyperlipidemia. Apolipoprotein A1 and B, acid lipase and lysosomal enzyme screening panel for 12 different enzymes were all normal. Several genes were sequenced to identify pathogenic mutations, including *G6PC* (glycogen storage disease (GSD) type IA), *GAA* (GSD type II), *AGL* (GSD type III), *SLC37A4* (GSD 1B, 1C, 1D), *LPL* (*LPL* deficiency type I), *APOC2* (hyperlipidemia), and *INSR*; all were reported as normal. No significant copy number variation was identified on chromosomal microarray analysis. Urine organic acids, acylglycines, and plasma amino acids and acylcarnitines were normal. The activity of CPT1 and CPT2 enzymes was

low normal in cultured skin fibroblasts (CPT1 = 0.47; normal 0.4–1.58 and CPT2 = 0.11; normal 0.16–0.57 nmol/min/mg protein). In response, the *CPT1A* and *CPT2* genes were sequenced, both reported as normal. By early infancy, she had failure to thrive (FTT) and was managed with foods high in calories and low in fat with medium chain triglycerides supplementation. Her head circumference increased from 42 cm (1st centile) at 13 months to 46 cm (10th centile) at 30 months of age with improved nutrition. MRI and MR spectroscopy of the brain was performed at 1.5 years of age and was reported as normal. Developmentally, the patient was appropriate for her age.

The proband (0091-01) and her parents (0091-02 and 0091-03) were enrolled in an IRB-approved study by the Gene Discovery Core of The Manton Center for Orphan Disease Research while she was an inpatient at Boston Children's Hospital (BCH). Blood samples were collected and processed for DNA extraction by the Research Connection Biobank Core at BCH. The remaining tissue from the diagnostic liver biopsy was collected for additional molecular analyses.

### Sequencing study and analysis

DNA from the proband and both biological parents was sent for whole exome sequencing (WES) to Axseq Technologies, Rockville, MD, USA. Samples were prepared as an Illumina sequencing library and enriched for exomic sequences



**Figure 1** Radio-pathologic and genetic findings in proband with *GPD1* mutation. (a) Liver biopsy: the liver parenchyma shows macro- and microvesicular fatty change on Hematoxylin and Eosin staining (H&E), magnification  $\times 10$ . (b and c) Ultrasound demonstrates diffuse hyperechogenicity of the liver with a fine granular pattern. In comparison, the gall bladder (GB) (b) and right kidney parenchyma (RK) (c) are hypoechogenic. (d) DNA sequence analysis of genomic PCR products illustrates three genotypes for *GPD1* c.686G>C seen in the family with proband homozygous, mother heterozygous and father WT for the allele. (e) Altered arginine residue (red) is evolutionarily well conserved in *GPD1* and *GPD1L* proteins in vertebrates and lower organisms including yeast. (f) Relative *GPD1* expression levels using copy number assay revealed father and proband to be *GPD1* haploinsufficient relative to the mother and two controls.

using the Illumina Exome Enrichment protocol. The captured libraries were sequenced using Illumina HiSeq 2000 Sequencers. The reads were mapped to the human genome assembly UCSC hg19 using Burrows–Wheeler Alignment (version 0.5.8). Single nucleotide polymorphisms (SNPs) and small insertions/deletions were called with SAMtools (version 0.1.7). The variants or SNPs were filtered using NHLBI exome variant server (<http://evs.gs.washington.edu/EVS/>) and dbSNP Build 137 databases.

PCR was performed to amplify the candidate gene (*GPD1*), reference sequence used was *GPD1*; NG\_032168.1, NM\_005276.3. Variants identified in *GPD1* were submitted to the Leiden Open Variant Database (LOVD) <http://databases.lovd.nl/shared/genes/GPD1>.

The following primers were used: *GPD1\_1F*: AGGAGGGGTCTTTCTCAC and *GPD1\_1R*: ATCAGGTACGACACACCACA, and the resultant amplified DNA was sent for Sanger Sequencing. Results were analyzed using the Sequencer 5.0 software and aligned with the wild-type (WT) gene sequence. Primers were also designed to sequence various SNPs adjacent to *GPD1*. The SNPs included: rs836180, rs200359712, rs201128732, rs2640533, rs147189770, rs10875996, rs4898546, rs7139363, rs836170, rs836171, rs113783111, rs836177, rs10783334, rs7964522, rs112386170, rs7964698, rs10735822, rs71464996, rs71441320, rs55639096, and rs12229758.

### Protein expression study

Western blot was performed to measure the levels of GPD1, GPD2, and CPT1A proteins in the liver tissue samples available from the patient and an age-matched control. The tissue was stored at  $-80^{\circ}\text{C}$  until analysis. Transferred proteins were probed with antibodies against GPD1 (HPA044620, 1:200 dilution, Sigma-Aldrich, St. Louis, MO, USA), GPD2 (Ag11036, 1:2000 dilution, Proteintech, Chicago, IL, USA), CPT1A ((Ag7202, 1:500 dilution, Proteintech, Chicago, IL, USA), and GAPDH (FL-335, 1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA) as control, and visualized using enhanced chemiluminescence. Quantification of protein levels was normalized to GAPDH using the program Quantity One 4.2.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) on an Image Station 440 (Kodak DS; Eastman Kodak co., Rochester, NY, USA).

### Taqman copy number assay

Taqman copy number assay (Life Technologies, Woburn, MA, USA) was performed on DNA from the proband, both parents and two controls. The probes for both *GPD1* (Hs00911535\_cn, FAM labeled) and copy number reference gene (4403326, VIC-labeled RNase P (*RPPH1*)) are commercially available. The assay was repeated twice and was performed in triplicate. Twenty nanogram (1  $\mu\text{l}$ ) of DNA was used per well with 12  $\mu\text{l}$  of Taqman Universal PCR master mix (Applied Biosystems, Woburn, MA, USA) and 1  $\mu\text{l}$  of each of the specific probes (target and control). A 7300 Real time PCR system from Applied Biosystems was used to perform the PCR and Sequence Detection software v1.4 for the interpretation of results. The DNA amplification based on the amplification plots was compared and mean cycle threshold ( $C_t$ ) values were obtained. The fold change in target and reference gene copy number, normalized to control was calculated using relative quantity =  $2^{-\Delta\Delta C_t}$ .

## RESULTS

### Proband carried *GPD1* mutation

WES was performed on DNA samples from the trio (both biological parents and the proband). The proband carried what appeared to be a homozygous mutation c.686G>C in the *GPD1* gene postulated to cause p.(R229P) amino-acid change. Sanger Sequencing confirmed the mutation (Figure 1d), and simultaneously, research group in Ontario using candidate gene analysis independently obtained the same result (personal communication from Robert Hegele). This residue is evolutionarily conserved (Figure 1e) and the mutation was not present in any of the publicly available SNP databases, whereas c.686G>A potentially causing p.(R229Q) change was identified in 1/13 005 chromosomes (frequency <0.0001) in exome variant server database. Further, Polyphen-2<sup>8</sup> score was 1, consistent with mutation


to be probably damaging, and SIFT analysis<sup>9</sup> revealed that this change was potentially not tolerated. Interestingly, although the mother was heterozygous for the mutation, the father was apparently homozygous for the WT allele. We hypothesized that the father may carry a deletion at the same locus inherited by the proband, or she may exhibit uniparental disomy for the maternal allele.

### *GPD1* haploinsufficiency in the proband and father

Taqman copy number assay was performed on the trio and two control DNA samples to evaluate if the father and the proband were haploinsufficient for *GPD1*. The sequence strand used to design the Taqman probe Hs00911535\_cn included the *GPD1* c.686 mutation locus (Chr 12:g.50,501,423). Probe 4403326 for *RPPH1* was used as reference. A *GPD1* deletion was observed in the proband and the father indicated by the presence of a single copy as compared with two copies present in the mother and two controls (Figure 1f). We suspect that the deletion is >1.85 kb in size as at a different *GPD1* locus (rs836180, Chr 12:g.50,503,269), the father was apparently homozygous for a SNP while both the proband and the mother were homozygous for the WT allele. To evaluate if the deletion involved genes adjacent (5' and 3') to *GPD1*, we genotyped several known SNPs located within *SMARD1* and *COX14* genes. Many of these SNPs were informative and there was no evidence of a deletion. On the basis of the location of genomic coordinates, we hypothesize that the deletion is smaller than 28.7 kb. In conclusion, the proband is compound heterozygous for two *GPD1* mutations, carrying a deletion from the father and missense change from the mother.

### Lack of *GPD1* protein in liver tissue sample from the proband

To evaluate the effects of these mutations, the available liver biopsy samples from the proband and an age- and sex-matched control were obtained from the Pathology Department. GPD1 antibody was used to probe for the GPD1 protein. Two bands were identified in the control corresponding to the two GPD1 isoforms of 37.5 kD (isoform 1) and 35 kD molecular weight (isoform 2) (Figure 2). Interestingly, isoform 1 was highly expressed in the control but was absent in the patient. In comparison, isoform 2 was expressed in small amounts in the control, whereas it was slightly increased in the patient. We suspect that for isoform 1, the missense mutation c.686G>A may affect splicing thereby creating an aberrant transcript that undergoes



**Figure 2** Western blot analysis on liver biopsy sample from the proband and age-matched control. GPD1 protein was absent in the proband although similar amounts of GPD2 and CPT1A were present in the proband and control.

nonsense-mediated decay. Further, the slight increase in isoform 2 noted in the patient may be secondary to the lack of isoform 1.

The level of GPD2, the mitochondrial isoform, was compared to determine if it was altered in response to GPD1 deficiency. We probed for GPD2 using a specific antibody and there was no evidence of a change in GPD2 levels in the proband.

The activity of both CPT1 and CPT2 enzymes was reduced in cultured skin fibroblasts from the proband but sequencing both the genes did not identify any pathogenic mutation. We assayed the amounts of CPT1A, the liver isoform of CPT1 using western blot, and did not find any significant difference between the patient and the control.

## DISCUSSION

We report for the first time a patient who inherited two heterozygous *GPD1* mutations, a deletion and a missense change. Our studies conclusively demonstrate that the two mutations resulted in GPD1 deficiency. The patient presented with FTT, vomiting, marked hepatomegaly, and hypertriglyceridemia since early infancy. The clinical findings were very similar to the 10 individuals from four consanguineous Israeli Arab families carrying a homozygous founder mutation c.361-1G>C in *GPD1*, who presented with vomiting, FTT, enlarged livers, and fasting hypertriglyceridemia (TG 258–6244 mg/dl).<sup>2</sup>

GPD1 is a member of the NAD-dependent GPD family. It has a major role in lipid biosynthesis by converting DHAP to G3P, which in turn is dephosphorylated to glycerol followed by acylation with fatty acids to form acylglycerol species. DHAP, an intermediate of glycolysis may not be converted to G3P due to GPD1 deficiency, causing relative excess of DHAP and a reduction in G3P. Indeed, in a mouse model of GPD1 deficiency, DHAP concentrations were significantly higher, and G3P lower when compared with the levels in WT mice in liver, muscle, and kidneys.<sup>10</sup> The mechanism of fatty liver in our patient may be due to acylation of excess DHAP. An acyl-DHAP pathway has been previously described where DHAP may first be acylated followed by reduction to 1-acyl-sn-G3P.<sup>11,12</sup> The acyl DHAP pathway is known to have a significant role in glycerolipid synthesis in mouse liver.<sup>12</sup>

The CPT1 and CPT2 activity were low normal in the patient's fibroblasts, but no mutations were identified in *CPT1A* and *CPT2* genes. Further, there was no reduction in the amounts of CPT1A protein in the liver. We suspect that the reduction in CPT1 and CPT2 activity may be secondary to the buildup of the DHAP and/or neutral fat in the cytoplasm. Malonyl CoA, an intermediate in the pathways of *de novo* fatty acid biosynthesis and fatty acid elongation, is also known to allosterically inhibit CPT.<sup>13</sup>

The diagnosis of GPD1 deficiency had significant implications in the management of the patient. Liver transplantation, previously considered for her, was not recommended after the molecular diagnosis. This was partly based on the outcome data in patients carrying *GPD1* mutation.<sup>2</sup> The oldest patient in the *GPD1* splicing mutation-carrying cohort from the Middle East was 23 years old,

and asymptomatic. Further, in eight of the ten affected patients, the triglyceride levels declined over time.

In conclusion, GPD1 deficiency represents a defect in the glucose and lipid pathways associated with severe hypertriglyceridemia and NASH. WES provided a diagnosis in this case where extensive clinical testing had failed to find a cause. The molecular diagnosis provided anticipatory information to the family, and guided the clinical management. Although developmentally appropriate at this time, this patient will need close follow-up as lack of GPD1 may interfere with the glycerol phosphate shuttle, and not allow certain cells to derive all their energy from glycolysis, specifically in brain cells that do not completely rely on the malate–aspartate shuttle to deliver cytosolic reducing equivalents to the mitochondrial matrix.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ACKNOWLEDGEMENTS

We acknowledge the financial support from the Gene Discovery Core of The Manton Center for Orphan Disease Research at Boston Children's Hospital. Sanger sequencing was performed by the Molecular Genetics Core Facility of the IDDRC at Boston Children's Hospital supported by National Institute of Health (NIH) P30HD18655. PBA was supported by K08 AR055072 from the NIH.

- 1 Menaya J, Gonzalez-Manchon C, Parrilla R, Ayuso MS: Molecular cloning, sequencing and expression of a cDNA encoding a human liver NAD-dependent alpha-glycerol-3-phosphate dehydrogenase. *Biochim Biophys Acta* 1995; **1262**: 91–94.
- 2 Basel-Vanagaite L, Zevit N, Har Zahav A *et al*: Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. *Am J Hum Genet* 2012; **90**: 49–60.
- 3 Peterfy M, Ben-Zeev O, Mao HZ *et al*: Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. *Nat Genet* 2007; **39**: 1483–1487.
- 4 Brahm A, Hegele RA: Hypertriglyceridemia. *Nutrients* 2013; **5**: 981–1001.
- 5 Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J: Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. *Mol Aspects Med* 2004; **25**: 495–520.
- 6 Mathur A, Sims HF, Gopalakrishnan D *et al*: Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. *Circulation* 1999; **99**: 1337–1343.
- 7 Cakir M, Bruno C, Cansu A, Cobanoglu U, Erduran E: Liver cirrhosis in an infant with Chanarin-Dorfman syndrome caused by a novel splice-site mutation in ABHD5. *Acta Paediatr* 2010; **99**: 1592–1594.
- 8 Adzhubei IA, Schmidt S, Peshkin L *et al*: A method and server for predicting damaging missense mutations. *Nat Methods* 2010; **7**: 248–249.
- 9 Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res* 2003; **31**: 3812–3814.
- 10 MacDonald MJ, Marshall LK: Mouse lacking NAD<sup>+</sup>-linked glycerol phosphate dehydrogenase has normal pancreatic beta cell function but abnormal metabolite pattern in skeletal muscle. *Arch Biochem Biophys* 2000; **384**: 143–153.
- 11 Hajra AK, Bishop JE: Glycerolipid biosynthesis in peroxisomes via the acyl dihydroxyacetone phosphate pathway. *Ann N Y Acad Sci* 1982; **386**: 170–182.
- 12 Agranoff BW, Hajra AK: The acyl dihydroxyacetone phosphate pathway for glycerolipid biosynthesis in mouse liver and Ehrlich ascites tumor cells. *Proc Natl Acad Sci USA* 1971; **68**: 411–415.
- 13 Saggerson D: Malonyl-CoA, a key signaling molecule in mammalian cells. *Annu Rev Nutr* 2008; **28**: 253–272.